Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| TURB | Turbo Energy | $5.85 | $2.07 | 54.76% | 16.6M | $42M | $0.57$20.45 |
| ANTX | An2 Therapeutics | $4.35 | $1.50 | 52.63% | 10.6M | $78M | $1.00$4.45 |
| DTCK | Davis Commodities | $2.18 | $0.75 | 52.45% | 21.4M | $39M | $1.32$137.80 |
| XENE | Xenon Pharmaceuticals | $61.72 | $19.78 | 47.16% | 447.3K | $3.5B | $26.74$62.40 |
| HIMS | Hims & Hers Health | $21.57 | $5.83 | 37.04% | 4.2M | $3.6B | $13.74$70.43 |
| RLMD | Relmada Therapeutics | $6.05 | $1.60 | 35.84% | 31M | $326M | $0.24$6.52 |
| EDSA | Edesa Biotech | $8.64 | $2.12 | 32.52% | 3.7M | $54M | $0.72$8.74 |
| PLYX | Polaryx Therapeutics | $3.55 | $0.81 | 29.56% | 418.4K | $130M | $2.20$48.91 |
| NERV | Minerva Neurosciences | $7.63 | $1.62 | 26.87% | 167.5K | $260M | $1.15$12.46 |
| DNTH | Dianthus Therapeutics | $82.44 | $17.24 | 26.44% | 87.9K | $2.8B | $13.37$84.78 |
| AGCC | Agencia Comercial Spirits | $22.88 | $4.77 | 26.34% | 1.3K | $623M | $3.66$22.88 |
| ATRA | Atara Biotherapeutics | $6.49 | $1.32 | 25.53% | 43.2K | $37M | $3.92$19.15 |
| RGNX | Regenxbio | $10.57 | $1.92 | 22.20% | 983.6K | $438M | $5.04$16.19 |
| QURE | uniQure | $17.36 | $3.09 | 21.65% | 8.7M | $879M | $7.76$71.50 |
| RNAC | Cartesian Therapeutics | $8.33 | $1.48 | 21.61% | 7.3K | $178M | $5.98$18.80 |
| JFB | Jfb Construction | $19.80 | $3.36 | 20.41% | 58.1K | $104M | $3.42$35.10 |
| LSTA | Lisata Therapeutics | $5.03 | $0.85 | 20.34% | 290.2K | $37M | $1.81$5.06 |
| BEG | Themes ETF Trust - Leverage Shares 2x Long Be Daily ETF | $31.36 | $5.22 | 19.96% | 28.6K | - | $10.89$50.61 |
| EDIT | Editas Medicine | $2.39 | $0.39 | 19.57% | 2.4M | $195M | $0.91$4.54 |
| KC | Kingsoft Cloud | $14.00 | $2.01 | 16.76% | 2.2M | $3.5B | $10.29$19.57 |
| VRTL | GraniteShares ETF Trust - GraniteShares 2x Long Vrt Daily ETF | $115.23 | $16.34 | 16.52% | 4.5K | - | $7.57$119.89 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $4.03 | $0.56 | 16.13% | 23.7M | - | $0.95$20.92 |
| TAOX | Tao Synergies | $4.57 | $0.60 | 15.11% | 61.4K | $30M | $1.84$11.98 |
| LXEO | Lexeo Therapeutics | $7.87 | $1.02 | 14.89% | 43.5K | $500M | $1.45$10.99 |
| BNTC | Benitec Biopharma | $12.99 | $1.65 | 14.55% | 109.3K | $390M | $9.85$17.15 |
| NBTX | Nanobiotix | $38.75 | $4.76 | 13.99% | 1.3K | $1.6B | $2.95$39.30 |
| HUHU | Huhutech International Group | $7.29 | $0.47 | 6.89% | 106.8 | $176M | $2.95$12.20 |
Related Articles
Featured Article
Hims & Hers Stock Pops 40%: Everything You Need to Know
Travis Hoium|Mar 9, 2026
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
Geoffrey Seiler|Feb 27, 2026
The company is looking toward international markets to boost its growth.
Hims & Hers HUGE Acquisition News!
Travis Hoium|Feb 19, 2026
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Selena Maranjian|Nov 24, 2025
It has grown wildly, and it could keep growing.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
